TY  - BOOK
AU  - Ghada Emam Abdelaziz
AU  - Dalia Abdelhamid Omran , 
AU  - Doha Abdelhamid Mokhtar , 
AU  - Rania Ahmed Ahmed Zayed , 
TI  - Impact of toll-like receptor 9 gene polymorphism (1237 t / c) on response to therapy in chronic hepatitis C Egyptian patients / 
PY  - 2016///
CY  - Cairo : 
PB  - Ghada Emam Abdelaziz , 
KW  - HCV
KW  - Polymorphism
KW  - TLR9
N1  - Thesis (M.Sc.) - Cairo University - Faculty of Medicine - Department of Clinical and Chemical Pathology; Issued also as CD
N2  - Background and aim: Hepatitis C virus (HCV) infection leads to  development of liver inflammation, causing morbidity and mortality. Multiple factors influence HCV progression, including genetic factors. Toll-like receptor 9 (TLR9) plays a key role in innate immunity and mutations in the  genes encoding this receptor have been associated with progression of liver damage. Our aim is to detect TLR9 1237 T/C (rs5743836) single nucleotide polymorphisms (SNP) in chronic hepatitis C Egyptian patients to determine  its association with susceptibility to infection, progression of fibrosis and response to treatment with interferon plus ribavirin. Results: genotype and allelic frequencies of TLR9 1237T/C SNP were not  significantly different between studied HCV-positive patients and controls (P=0.373 and 0.405, respectively). TLR9 1237T/C SNP was not associated to  treatment response, either ETR or SVR [OR (95% CI) of 0.834 (0.263{u2013}2.643)  and 0.698 (0.253{u2013}1.928), respectively) and was not related to advanced stage  of fibrosis (P= 0.183). Baseline AFP level was significantly higher in patients with advanced hepatic fibrosis (P= 0.000). Conclusion: TLR9 1237T/C (rs5743836) SNP is not associated to  susceptibility to HCV infection, progression of fibrosis or response to combined treatment with Peg-INF plus ribavirin in HCV infected Egyptian  patients.
ER  -